House Sends NACDS-Backed “Gag Clause” Prohibition to President Legislation prevents restrictions on pharmacists’ ability to tell patients when they can save money on prescriptions by paying cash instead of using insurance;NACDS positions DIR fee reform as another crucial issue for lowering out-of-pocket drug costs

2018-09-25T17:03:37+00:00Sep-25-18|Categories: Press Release|Tags: , , |

The legislation will prevent restrictions on pharmacists’ ability to tell patients when they can save money on prescriptions by paying cash instead of using insurance. Meanwhile, NACDS positions DIR fee reform as another crucial issue for lowering out-of-pocket drug costs.

NACDS Addresses DIR Fees, Other “Access Agenda” Priorities in National Drug-Pricing Policy Discussion NACDS responds to request-for-information from HHS Secretary Azar for “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs”

2018-07-18T16:25:32+00:00Jul-18-18|Categories: Press Release|Tags: , , , , |

NACDS has submitted comments to Health and Human Services Secretary Alex Azar in response to the agency’s request-for-information on drug-pricing public policy issues.

NACDS RxIMPACT Rallies Senate Support for Action on DIR Fees Urging Senators to sign letter to HHS Secretary is the most recent action of NACDS’ grassroots advocacy program on this pressing issue

2018-07-11T12:20:12+00:00Jul-11-18|Categories: Press Release|Tags: , , , , |

NACDS RxIMPACT pharmacy advocates are urging Senators to sign a letter to U.S. Secretary of Health and Human Services Secretary Alex Azar that is being led by Sen. Shelley Moore Capito (R-WV) and Sen. Jon Tester (D-MT).

NACDS Comments to CMS on Medicare Prescription Drug Program Urges Medicare Part D policies related to DIR fee fairness, opioid abuse prevention, prescription drug affordability, and patients’ pharmacy access

2018-01-17T09:58:38+00:00Jan-17-18|Categories: Press Release|Tags: , |

NACDS expressed support for, and provided further input, on CMS’ proposed rule, which involves issues including direct and indirect remuneration fees; e-prescribing; medication therapy management; opioid abuse; and fostering pharmacy access.

Load More Posts